Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Breast Neoplasms 61Carcinoma, Renal Cell 39Neoplasm Metastasis 38Neoplasms 24Kidney Neoplasms 20Neuroendocrine Tumors 19Recurrence 16Prostatic Neoplasms 15Head and Neck Neoplasms 13Tuberous Sclerosis 12Triple Negative Breast Neoplasms 12Lymphoma, Mantle-Cell 11Hodgkin Disease 11Precursor Cell Lymphoblastic Leukemia-Lymphoma 10Lymphoma, Large B-Cell, Diffuse 10Lymphoma 10Colorectal Neoplasms 10Waldenstrom Macroglobulinemia 9Stomach Neoplasms 9Multiple Myeloma 9Leukemia, Lymphocytic, Chronic, B-Cell 9Glioma 9Glioblastoma 9Brain Neoplasms 9Sarcoma 8Pancreatic Neoplasms 8Melanoma 8Lymphoma, Follicular 8Lung Neoplasms 8Carcinoma, Non-Small-Cell Lung 8

Interventions

Cyclophosphamide 5pegaspargase 3Vincristine 3Methotrexate 3Mercaptopurine 3Etoposide 3Dexamethasone 3Cytarabine 3fludarabine 2Radiotherapy 2N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 2Karyotyping 2Injections, Spinal 2Idarubicin 2Doxorubicin 2nelarabine 1mogamulizumab 1Positron Emission Tomography Computed Tomography 1Panobinostat 1Mitoxantrone 1Melphalan 1Everolimus 1Clofarabine 1Calcium Dobesilate 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Leukemia, T-Cell × Everolimus × Clear all
NCT00081874 2025-04-27

RAD001 in Relapsed or Refractory AML, ALL, CML in Blastic-Phase, Agnogenic Myeloid Metaplasia, CLL, T-Cell Leukemia, or Mantle Cell Lymphoma

M.D. Anderson Cancer Center

Phase 1/2 Completed
29 enrolled
LymphoidMyeloidOther hematologic neoplasm

Leukemia, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, T-Cell, Leukemia, Myeloid, Acute, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡